Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs KB Financial Group, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while KB Financial Group, Inc. trades at $117.53 (market cap $42.79B). The key difference: KB Financial Group, Inc. is far larger — about 4.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and KB Financial Group, Inc. pays a 2.6% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | KB | |
|---|---|---|
Market Cap | $9.39B | $42.79B |
Sector | Health | Financials |
52-Week High | $356.25 | $124.01 |
52-Week Low | $241.71 | $77.50 |
Enterprise Value | $9.14B | — |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
KB Financial Group (KB) trades at $124.01, up 2.22% today, with a bullish technical outlook from moving averages and recent momentum. The stock shows strong fundamentals, with net income margin at 27.82% and a P/E ratio of 11.03, indicating potential undervaluation. Recent earnings beats in Q1 and Q2 2026, alongside positive news coverage on diversification efforts, support investor confidence.
The outlook for KB is positive, driven by earnings growth and strategic expansion into non-banking segments. Risks include volatile cash flow trends and high interest expenses. Analyst consensus is mixed but leans hold, with institutional interest steady. Upside potential exists if profitability trends continue, though macroeconomic factors could pressure performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
